Immunotherapy
Cancer treatment that trains the patient's own immune system to attack tumors.
Coverage of Immunotherapy is holding steady : 14 signals on the latest tracked day, up 17% from its three-week baseline of 12, across 4 domains (unchanged from a week ago). That makes it the #39 most-covered of the 348 concerns we track.
What’s changed
6 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- Pan-cancer single-cell atlas of immunotherapy response identifies ZNF385A as a regulator of immune evasion in small cell lung cancer. · Biochim Biophys Acta Mol Basis Dis · 2026-08-29
- A Case of POLE-Mutated, dMMR/MSI Colorectal Cancer With an Exceptional Response to Immunotherapy. · Am J Ther · 2026-08-26
- Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy. · Eur J Med Chem · 2026-08-25
- Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer. · Immunotherapy · 2026-08-24
- Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report. · J Immunother Precis Oncol · 2026-08-24
- Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. · Ann Med · 2026-08-24
What the reporting says
It shows up alongside Colorectal Cancer (200), MSI-H (40), Lung Cancer (36), Icis (17), KRAS (14), ctDNA (13), Chen (16), FDA (29).
Two steps out: Braf (through Colorectal Cancer, 69 shared stories on the weaker link); Wang (through Colorectal Cancer, 63 shared stories on the weaker link); Systematic Review (through Colorectal Cancer, 45 shared stories on the weaker link); Egfr (through Colorectal Cancer, 43 shared stories on the weaker link).
Tracked since Dec 31, with coverage on 107 separate days — concentrated in Oncology and Pubmed Targeted.